[Technical Problem] The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. [Solution to Problem] Responsiveness to cancer immunotherapy is predict by determining a relative value of a CD4+T-cell subpopulation, dendritic cell subpopulation, and/or CD8+T-cell subpopulation correlated with a dendritic cell stimulation in an anti-tumor immune response in a sample derived from a subject. A composition for treating or preventing cancer comprising cells such as CD62LlowCD4+T-cells is also provided.[技術問題] 本發明係關於基於個體之T細胞組合物而預測該個體對癌症免疫療法之反應，及基於該預測使用癌症免疫療法之治療性方法。本發明亦提供一種用於改良或維持個體對癌症免疫療法之反應的方法。 [問題之解決方案] 對癌症免疫療法之反應藉由判定與來源於個體之樣本中之抗腫瘤免疫反應中的樹突狀細胞刺激相關的CD4+T細胞亞群、樹突狀細胞亞群及/或CD8+T細胞亞群之相對值來預測。亦提供一種用於治療或預防癌症之組合物，其包含諸如CD62LlowCD4+T細胞之細胞。
